---
archetype: bookmark
categories:
- genomics
date: 2019-02-04T12:14:25Z
description: Last month, the DNA-testing company 23andMe secured Food and Drug Administration
  approval for a new screening for gene-based health risks.
dropmark.editURL: http://radhikan.dropmark.com/616548/17640452
featuredImage: /img/content/post/nytimes-why-you-should-be-careful-about-23andme-s-health-test.jpg
link: https://www.nytimes.com/interactive/2019/02/01/opinion/23andme-cancer-dna-test-brca.html
linkBrand: nytimes.com
slug: nytimes-why-you-should-be-careful-about-23andme-s-health-test
source:
  name: Dropmark
  apiendpoint: https://shah.dropmark.com/616548.json
title: Why You Should Be Careful About 23andMe’s Health Test
---
Last month, the DNA-testing company 23andMe secured Food and Drug Administration approval for a new screening for gene-based health risks. Along with celiac disease, Alzheimer’s, Parkinson’s, breast cancer and several other medical conditions, the company can now screen clients for two mutations that have been linked to colorectal cancer.

